Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Online ISSN 1827-1820
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
Psoriasis is a skin disease of an inflammatory nature, chronic, relapsing requiring long- term treatment and in many cases involves a reduction in the quality of life. Treatment with biologics is indicated in patients with moderate to severe psoriasis who do not respond or cannot be treated with conventional systemic drugs, and therapeutic goal is an equal or greater PASI-75 improved induction phase and keep long term in the maintenance phase. Before starting treatment with a biological agent it is necessary to review the contraindications and precautions, rule out latent TB infection and complete the pending immunizations. Biological agents have a more favorable safety profile than classical systemic treatments; the most common side effects are mild and rarely involve the discontinuation of treatment. The treatment decision will be based on individual characteristics and patient preferences, functional limitation, expected speed of onset of effect, adverse reactions, availability and cost of treatment.